US Patent 6,682,734: What the Claims Cover, What’s Missing, and Where the Landscape Holds
US Patent 6,682,734 claims a combination regimen for B cell lymphoma that pairs (i) a chimeric anti-CD20 antibody produced from a specific transfectoma deposit (ATCC 69119) with (ii) a radiolabeled anti-CD20 antibody produced from a specific hybridoma deposit (ATCC HBE 1388). The method also includes defined dose ranges, dosing cadence, radionuclide selection (I-131, Y-90), optional diagnostic imaging with In-111, and an optional stem-cell or bone-marrow harvest and reinfusion step.
What is claimed in US 6,682,734 (claim-by-claim map)?
Core inventive combination
Claim 1 sets the spine of the invention.
| Claim |
Limitation (short form) |
What is anchored to deposits / chemistry |
| 1 |
Treat B cell lymphoma by administering: (a) chimeric anti-CD20 antibody from ATCC deposit 69119 at a first time; (b) radiolabeled anti-CD20 antibody from ATCC deposit HBE 1388 at another time |
Defines both antibody sources via ATCC deposits; requires sequencing rather than co-administration |
Dose and schedule tuning around the chimeric antibody (not the radiolabeled antibody)
Claims 2-5 define dosage bands and an example schedule for the chimeric antibody from ATCC 69119.
| Claim |
Additional limitation |
Numerical boundaries |
| 2 |
Dose of chimeric anti-CD20 antibody |
0.001 to 30 mg/kg |
| 3 |
More preferred dose |
0.01 to 25 mg/kg |
| 4 |
Most preferred dose |
0.4 to 20.0 mg/kg |
| 5 |
Dosing frequency and duration |
once weekly for ~2 to 10 weeks |
Radiolabel specification (what radionuclides fall in)
Claims 6-7 define radionuclide options and a dose example for I-131.
| Claim |
Additional limitation |
Numerical boundaries / allowed radionuclides |
| 6 |
Radiolabel selection |
I-131 or Y-90 |
| 7 |
If I-131, dose per single treatment dosage |
5 to 40 mCi |
Optional diagnostic pre-dose (Imaging before therapy)
Claims 8-10 cover diagnostic radionuclide dosing prior to the therapeutic radiolabeled anti-CD20 antibody.
| Claim |
Additional limitation |
Numerical boundaries / radionuclides |
| 8 |
Diagnostically effective amount of diagnostic radionuclide labeled anti-CD20 antibody before therapeutic radiolabeled antibody |
No number in claim text provided |
| 9 |
Diagnostic radionuclide is In-111 |
Defines In-111 as diagnostic radionuclide |
| 10 |
Diagnostic dose limit for In-111 |
< 5 mCi |
Relationship between the diagnostic antibody and the therapeutic antibody sources
Claim 11 links which anti-CD20 antibody forms can be used in the diagnostic regimen.
| Claim |
Additional limitation |
| 11 |
Diagnostic radionuclide-labeled anti-CD20 antibody comprises either: (a) chimeric anti-CD20 from ATCC 69119 or (b) anti-CD20 from hybridoma ATCC HB11388 |
Stem-cell / bone marrow harvest and reinfusion (adjunct procedure)
Claims 12-13 add an optional but explicit post-therapy supportive step.
| Claim |
Additional limitation |
| 12 |
Prior to radiolabeled anti-CD20 antibody administration, harvest peripheral stem cells or bone marrow |
| 13 |
Reinfuse harvested stem cells or bone marrow |
What do these claims actually “cover” in practice?
1) A sequence-locked regimen
The claim language in 1 requires two administrations at two different periods: chimeric anti-CD20 first, then radiolabeled anti-CD20 later. A product labeled as anti-CD20 that is co-administered simultaneously may still fall outside the claim if sequencing is treated as a material limitation during claim construction.
2) The antibody is functionally defined by ATCC deposits
The chimeric antibody must be “derived from a transfectoma having ATCC deposit number 69119.” The radiolabeled anti-CD20 must be “derived from a hybridoma having ATCC deposit number HBE 1388.” This makes the claim narrower than a general “any anti-CD20 + radio-anti-CD20” approach. It also makes the claim sensitive to what constitutes “derived from” these deposits.
3) Dosage bands are asserted only for the chimeric antibody
The only explicit mg/kg ranges in your claim text are for the ATCC 69119 chimeric antibody (claims 2-4). The radionuclide dose range provided is for the I-131 radiolabeled antibody (5 to 40 mCi, claim 7). The Y-90 dose band is not stated in the excerpt you provided; that omission affects how far the Y-90 embodiment reaches.
4) The optional imaging pre-dose creates a separate infringement pathway
If a regimen is used that includes In-111 diagnostic imaging with an anti-CD20 derived from 69119 or HB11388, claims 8-11 may be implicated even if later therapeutic radionuclide dosing differs, depending on how “prior to administration” and “diagnostically effective amount” are construed.
5) The stem-cell/bone marrow harvest step adds a second procedural hook
Claims 12-13 turn the method into a combined oncology workflow, not only a drug sequence. If stem-cell harvesting is part of the clinical protocol (for example, intensified therapy with autologous support), this portion can broaden practical relevance to high-intensity lymphoma protocols.
Where does the risk sit: novelty, obviousness, and non-obvious sequencing?
What looks strongest for patentability
The combination locks in:
- The anti-CD20 antibody source by ATCC deposit for both the “cold” chimeric antibody and the radiolabeled antibody, and
- A sequencing requirement (first chimeric dosing, then radiolabeled dosing), and
- Specific radionuclides (I-131 or Y-90) and specific I-131 dose range for the radiolabeled antibody, and
- Optional In-111 diagnostic imaging prior to therapy, and
- Optional stem-cell/bone-marrow harvest and reinfusion.
If those deposits correspond to specific CD20 antibody constructs that were not the default standards used in prior art combination regimens, then the novelty rests on the targeted pairing, not just on the concept of radioimmunotherapy.
What looks most vulnerable
The claims include dose ranges and schedule language that can be attacked as routine optimization if prior art already taught:
- Anti-CD20 pre-dosing before radioimmunotherapy,
- Use of I-131 or Y-90 anti-CD20 radiolabeled antibodies in lymphoma,
- Use of In-111 anti-CD20 imaging,
- Use of therapeutic intensification with stem-cell or bone-marrow support.
For obviousness analysis, combination claims in oncology are often vulnerable when:
- Each component was known,
- The sequencing was known or rendered obvious by mechanistic reasoning,
- The dose windows reflect typical titration practices rather than an unexpected property.
Material claim-construction dependencies
The patent lives or dies on interpretive questions that are not “cosmetic”:
- “Derived from” the specific ATCC deposits: if courts interpret “derived from” strictly, it narrows infringement; if broad, it increases reach.
- “Another administration period”: this is likely to be construed as a non-identical dosing time relative to the first period, but the boundary (same day vs different days vs weeks) can matter.
- “Radiolabeled anti-CD20 antibody”: if a therapeutic antibody is radiolabeled with a radionuclide not listed (other than I-131 or Y-90), the claim may fall outside claim 6 even if it is anti-CD20 radioimmunotherapy.
How does this landscape relate to competitive strategies?
Competitive space defined by three design knobs
-
Which anti-CD20 antibody
- This patent narrows to antibodies tied to ATCC 69119 (chimeric) and ATCC HBE 1388 (radiolabeled source).
- Competitive entrants that use different anti-CD20 scaffolds or different producer lines can create design-around by changing the antibody source definition.
-
Which radionuclide
- This patent explicitly enumerates I-131 and Y-90 as acceptable radiolabels (claim 6).
- Design-around by selecting other radionuclides (even with anti-CD20 radioimmunotherapy) can avoid claim 6, unless another claim language captures those variants.
-
Whether they include pre-dosing and imaging
- If a competitor omits the cold chimeric anti-CD20 pre-administration window, claim 1 may not be met.
- If a competitor omits diagnostic In-111 pre-dose steps, claims 8-11 are avoided.
- If a competitor omits stem-cell harvest/reinfusion, claims 12-13 are avoided.
What this means for business and R&D
- The claim architecture supports a “watch-list” focus on protocols that include both a cold anti-CD20 pre-dose and a radiolabeled anti-CD20 therapy with I-131 or Y-90, especially where In-111 imaging and/or stem-cell support is used.
- The ATCC deposit language indicates that the patent is not just covering the therapeutic concept; it is attempting to pin the claimed embodiments to specific antibody lineages.
What is missing from the claims as provided (and why it matters to validity and freedom-to-operate)?
Your excerpt supplies the claim set text, but it does not provide:
- The exact antibody identities corresponding to ATCC 69119 and HBE 1388 (for example, whether they are chimeric variants comparable to Rituxan-like constructs, or distinct clones),
- The relationship between therapeutic and diagnostic embodiments beyond the limited diagnostic claim 11,
- The full claim set beyond claim 13 (only claims 1-13 are shown),
- The patent prosecution history, office actions, or construed claim interpretations.
Those omissions are critical because:
- If ATCC 69119 corresponds to the same chimeric CD20 used in widely marketed therapies, the claim’s “novelty” may be undermined by broad prior use of anti-CD20 pre-dosing with radioimmunotherapy.
- If ATCC 69119 and HBE 1388 correspond to specific earlier CD20 radioimmunotherapy programs, the sequencing and dose ranges may be viewed as obvious optimizations.
Key takeaways
- US 6,682,734 is a sequencing-and-lineage-locked combination patent: cold chimeric anti-CD20 from ATCC 69119 followed by radiolabeled anti-CD20 from ATCC HBE 1388 for B cell lymphoma.
- The claim set narrows heavily on which antibody sources are used and on which radionuclides are allowed (I-131 or Y-90).
- It adds practical “hooks” for dosage windows (mg/kg for the cold antibody; mCi for I-131), optional In-111 diagnostic pre-dosing, and optional stem-cell/bone-marrow harvesting and reinfusion.
- The strongest freedom-to-operate risk concentrates where protocols include: (i) anti-CD20 pre-dosing, (ii) anti-CD20 radioimmunotherapy with I-131 or Y-90, and (iii) timing separation between administrations.
FAQs
-
Does the patent cover co-administration of the cold anti-CD20 and radiolabeled anti-CD20?
The claims require administration at “a first administration period” and “another administration period,” which reads as sequencing rather than simultaneous dosing.
-
Which radiolabels are explicitly covered for the therapeutic radiolabeled anti-CD20 antibody?
The claims list iodine [131] and yttrium [90] (claim 6).
-
Is the diagnostic imaging step mandatory for infringement of claim 1?
No. Claims 8-11 add the diagnostic pre-dose as separate dependent claim limitations; claim 1 does not require diagnostic In-111.
-
Are dose ranges provided for Y-90?
The provided text gives an I-131 mCi range (claim 7) but no Y-90 dose range in the excerpt.
-
Does the method require stem-cell harvesting and reinfusion?
No. That is limited to dependent claims 12-13; claim 1 does not include that procedural step.
References
[1] US Patent 6,682,734, “Method for the treatment of B cell lymphoma,” claims 1-13 (provided claim text in user prompt).
